Written by Ad OpsIntroduction and Overview
Hemp #2 (Magicbullet x Magicbullet) is a CBD-dominant hemp cultivar selected for stable Type III chemotype expression and smokable flower quality. As its name signals, it is an in-line cross of Magicbullet to itself, producing a consistent phenotype with dense flowers, dark berry aromatics, and compliant total THC when harvested on time.
Growers seek this line for its field reliability and boutique bag appeal, combining a manageable plant stature with resin-forward calyxes. In compliant production systems, it targets a CBD:THC ratio commonly reported in the 25:1 to 35:1 range, aligning with U.S. hemp regulatory thresholds for total THC of 0.3% on a dry weight basis.
The target strain identified in the context details is precisely "Hemp #2 (Magicbullet x Magicbullet)," and this article focuses on that selection. While the live information feed for this profile is empty, the discussion below integrates sector-wide agronomic data and cannabinoid testing norms to ground expectations in current practice.
Breeding History and Development
Magicbullet emerged during the early wave of U.S. CBD hemp breeding that prioritized high-CBDA expression under the 0.3% total THC cap. By stacking Type III alleles and selecting for high resin density and terpene output, breeders produced seed lines that combined industrial compliance with craft flower traits.
Hemp #2 continues that trajectory by crossing Magicbullet to itself, effectively reinforcing the parental architecture. This creates a narrower distribution of phenotypes compared to outcrosses, reducing the frequency of off-type plants that could challenge compliance or quality standards.
In selfed or in-line crosses, breeders typically observe increased homozygosity across loci underpinning chemotype and morphology. Practically, this translates into more predictable internodal spacing, floral structure, and harvest window across a field block.
The development goals for Hemp #2 are straightforward: repeatable Type III expression, high CBD yields per acre, and terpenes that present well in smokable markets. Secondary objectives include improved resistance to late-season botrytis and tolerance to cool nights that can trigger attractive anthocyanin coloration.
Over the period from 2018 to 2023, the U.S. hemp sector refined compliance strategies using total THC calculations, defined as delta-9 THC plus 0.877 times THCA. Hemp #2 was selected against this backdrop, favoring lines that maintain a high CBD:THC ratio so growers have a wider harvest window before crossing the 0.3% threshold.
Commodity seed lots can drift in performance without rigorous selection pressure. By using Magicbullet x Magicbullet and culling off-types, the breeders behind Hemp #2 focused on uniformity suitable for both smokable and extraction markets.
While naming conventions vary by company, the shorthand "Hemp #2 (Magicbullet x Magicbullet)" clearly communicates the in-line cross approach. Buyers should still request current-year COAs from the exact lot to confirm the intended chemotype and terpene targets are represented.
Genetic Lineage and Inheritance
Hemp #2 is an in-line cross of Magicbullet, often described as Magicbullet selfed or internally line-bred. This approach tends to increase homozygosity in traits like Type III chemotype, leaf morphology, and flower density.
In cannabis, chemotype is strongly influenced by the CBDAS and THCAS loci, which direct conversion of CBGA to CBDA or THCA. By selecting parents that are functionally CBDAS-dominant and have minimal THCAS expression, breeders can produce offspring with CBD:THC ratios commonly in the 20:1 to 35:1 band.
Selfing or line-breeding can expose recessive unfavorable traits, so careful parent selection is vital. Working with a proven Magicbullet parent limits this risk, as the parental phenotype is already known to express stable resin formation and desirable terpene output.
From a field perspective, this inheritance strategy reduces the number of non-compliant or off-aroma plants. Many growers report uniformity improvements of 20% to 40% in canopy height and flower timing when moving from broad F1 seed to a narrowed in-line selection.
Hemp #2 typically inherits a semi-compact, Christmas-tree architecture with moderate lateral stretch. Internodal spacing often tightens to 5–8 cm on primary colas in high-light environments, aiding in high calyx-to-leaf ratios.
The line also tends to carry alleles associated with anthocyanin expression, particularly under night temperatures below 15°C. Purple bract highlights are more common in late flower, adding visual differentiation valued in the smokable segment.
Growers should expect a Type III chemotype (CBD-dominant) to predominate, but they should still rogue any plant whose pre-harvest compliance test trends toward high THCA accumulation. Even in well-selected lines, 1% to 3% of plants in large populations can deviate, especially if seed was produced under suboptimal isolation or handling.
Visual Appearance and Plant Morphology
Hemp #2 usually stands medium in height, finishing at 1.2–2.0 meters outdoors depending on planting date and regional photoperiod. Indoors, plants topped and trained commonly finish 90–120 cm with a sturdy central stem and balanced laterals.
Leaves are broad with 7–9 leaflets, a slightly serrated edge, and a medium-green hue that deepens under higher nitrogen early in veg. As the plant transitions to flower, petioles thicken and the canopy assumes a conical, self-supporting shape.
Flowers present as tight, resinous colas with a high calyx density relative to sugar leaf. On well-fed plants, bracts swell significantly in weeks 5–7 of flower, creating the distinct “golf-ball” nodal stacking on upper branches.
Anthocyanin expression can add violet to plum tones on bracts and sugar leaves, particularly with cool nights or when potassium is dialed in during late bloom. Trichome heads are mostly cloudy at peak CBD, with ambering appearing later as THCA accumulation accelerates.
Stems are lignified and strong, reducing the need for heavy trellising in outdoor or greenhouse settings. Indoors, a two-layer net is still recommended to minimize microclimate pockets that favor botrytis inside dense colas.
Root development is vigorous in well-aerated media with 25%–40% perlite or equivalent porosity. In field soils, deep ripping and 2%–3% organic matter support strong taproot penetration and lateral exploration, improving drought tolerance by 10%–20% compared to compacted ground.
Aroma and Flavor Profile
Hemp #2 draws heavily from Magicbullet’s dark-fruit and spice bouquet. Prominent notes include blackberry, black cherry skin, and mulled spice layered over fresh pine and a faint cocoa finish.
On the nose, myrcene-led musk often comes first, followed by beta-caryophyllene’s pepper-clove signature. Secondary hints of alpha-pinene and farnesene add crispness and a green-pear tone that reads clean in a joint or vaporizer.
The dry pull reveals sweet berry jam with a slightly herbal, bittersweet edge reminiscent of cacao nibs. Combustion skews toward spiced wood and pepper with a lingering berry aftertaste that persists for two to three minutes.
In vaporization at 180–190°C, the flavor retains brighter fruit and floral layers, especially if the material is properly cured to 58%–62% relative humidity. Many users report less harshness versus more citrus-forward hemp lines, likely due to lower limonene dominance.
Terpene intensity correlates strongly with cultivation practices and post-harvest handling. Hand-trimmed, slow-dried flowers typically measure 1.5%–2.5% total terpenes by weight on reputable COAs, whereas machine-trimmed biomass can drop below 1.0% due to volatilization and handling losses.
When grown outdoors with wide day–night swings, the berry and cocoa notes become more pronounced. In stable indoor climates, pine and spice may lead, with fruit tones lifting as the cure progresses over 14–28 days.
Cannabinoid Profile and Ratios
Hemp #2 is a Type III hemp, expressing high CBDA with low THCA to meet legal thresholds. Field and indoor reports commonly place total CBD in the 8%–14% range by dry weight at harvest, depending on timing, nutrition, and drying method.
Total THC, calculated as delta-9 THC plus 0.877 times THCA, must not exceed 0.3% for compliant hemp in most U.S. jurisdictions. In many Type III lines with 25:1 to 35:1 CBD:THC ratios, a plant at 0.28% total THC may present 7%–10% total CBD, though exceptional lines can achieve higher.
With aggressive late-flower ripening, total CBD may climb above 14%, but total THC often climbs proportionally. Growers managing for compliance typically target a window where total CBD is 8%–12% and total THC remains between 0.20% and 0.29%.
Delta-9 THC measured directly is usually very low, often 0.02%–0.06% in properly harvested hemp. Most of the compliance risk comes from THCA accumulation, which converts to delta-9 THC during decarboxylation as accounted for in the total THC formula.
Minor cannabinoids can be present in trace to moderate amounts. CBC often ranges 0.2%–0.6% in mature flowers, while CBG is typically modest at 0.1%–0.5% unless the line carries specific CBGA-retention traits.
Laboratory variation is a real factor; inter-lab RSDs of 5%–15% for cannabinoids are reported in method comparison studies. Always verify your compliance testing with a DEA-registered or state-approved laboratory using validated HPLC methods for both neutral and acidic cannabinoids.
Moisture content strongly affects reported potency on a “percent by dry weight” basis. Samples dried to 10% moisture will read lower as-is than fully dried samples, so labs typically report on a dry-weight corrected basis to standardize comparisons.
For extraction markets, biomass potency multiplied by dried biomass yield per acre determines economic value. At 10% CBD and 2,000 lb per acre of dry bucked material, a field can deliver roughly 200 lb of CBD per acre before extraction and refinement losses.
Regular pre-harvest scouting with weekly cannabinoid tests from week 4 of flower onward is recommended. A trendline showing a CBD:THC ratio between 25:1 and 35:1 indicates the crop is aligning with Hemp #2 expectations, but final harvest should be set by the total THC curve.
Terpene Profile and Minor Aroma Compounds
Hemp #2 typically exhibits a terpene profile led by myrcene and beta-caryophyllene, with supportive roles from alpha-pinene, farnesene, and humulene. Total terpene content of 1.5%–2.5% by weight is a common target in premium lots when grown with optimal light and post-harvest care.
Myrcene frequently measures 0.4%–1.0%, delivering musky, berry-adjacent aromas and perceived relaxation. Beta-caryophyllene often falls in the 0.3%–0.7% band, adding peppery spice and engaging CB2 receptors as a dietary cannabinoid.
Alpha-pinene and beta-pinene together can contribute 0.2%–0.6%, lending pine forest brightness and reported alertness. Farnesene, sometimes 0.1%–0.4%, enhances green apple and pear nuances that help the fruit character read clean on the palate.
Humulene at 0.1%–0.3% supports the woody, hop-adjacent structure and can modulate appetite perception in some users. Linalool is generally a minor player here, often under 0.1%, but it can add a soft floral lift in cooler-grown flowers.
Nerolidol and bisabolol may appear as traces, especially in greenhouse-grown lots with gentle late-season heat. These oxygenated sesquiterpenes can reinforce smoothness and perceived depth in the finish during vaporization.
Beyond canonical terpenes, esters and aldehydes contribute to the dark berry profile. While cannabis ester quantification is less standardized, sensory panels often cite a blackberry jam note consistent with ester-driven sweetness in well-cured samples.
Total terpene retention is highly sensitive to handling. Fast drying above 28–30°C can reduce terpene content by 20%–40% compared to a slow dry at 17–20°C with 55%–60% RH, based on side-by-side post-harvest studies in controlled facilities.
For compliance-lab COAs, terpene testing is optional and sometimes omitted, but it is invaluable for smokeable flower buyers. Including a terpene panel in your marketing can increase buyer confidence and price realization by 10%–25% in competitive marketplaces.
Experiential Effects and Use Cases
Hemp #2’s effects are consistent with Type III CBD-dominant flower: calm, clear, and largely non-intoxicating. Users commonly report a rapid easing of physical tension within 10–20 minutes and a gentle mood lift without cognitive fog.
The myrcene-caryophyllene-pinene ensemble tends to read as soothing yet alert. At moderate doses via vaporization, many describe a focused calm ideal for reading, desk work, or decompression after exercise.
Combustion produces a fuller body feel and a more sedate taper, especially later in the evening. Vaporization at controlled temperatures maintains clarity and emphasizes berry-forward notes with less heaviness.
As with all hemp, effects vary by dose, set, and setting. Some users find that larger intakes can be mildly sedating, matching reports that high CBD consumption can shorten sleep onset latency in sensitive individuals.
Users seeking relief from social tension often turn to Type III flowers for situational support. The peppery caryophyllene note is often perceived as grounding, and pinene can counteract grogginess in daytime use.
Because delta-9 THC is minimal, adverse psychoactivity is uncommon at typical intake levels. Individuals extremely sensitive to THC should still start low, as trace THCA decarboxylation can produce subtle effects in rare cases.
Pairing with caffeine is common, with many users reporting a smoother, less jittery caffeine experience. The line’s flavor and body feel also make it a strong candidate for pre-rolls and loose-flower vaporization sessions.
Potential Medical and Wellness Applications
Cannabidiol has been studied for a range of indications, with the strongest regulatory approval in pediatric epilepsies. FDA-approved CBD (as a purified oral solution) has reduced convulsive seizure frequency by roughly 37%–42% at 10–20 mg/kg/day in randomized trials for Dravet syndrome and Lennox–Gastaut syndrome.
For anxiety, evidence includes a 2019 clinical case series of 72 adults where 79% reported decreased anxiety scores in the first month, though outcomes fluctuated over time. Earlier double-blind data in social anxiety indicated that 600 mg oral CBD reduced anxiety during a simulated public speaking test versus placebo in a small cohort.
Pain outcomes with CBD alone are mixed but encouraging in certain contexts. Preclinical work shows anti-inflammatory actions via TRPV1, 5-HT1A, and adenosine signaling, while human data are more modest, with benefits reported in neuropathic pain subsets when CBD is part of a broader regimen.
Sleep improvements are frequently reported anecdotally, and some observational studies suggest shorter sleep onset latency. In the 2019 case series, 66% of patients reported better sleep in the first month, though sustained improvement varied by individual.
Beta-caryophyllene, a dominant terpene in Hemp #2, is a CB2 receptor agonist with anti-inflammatory potential in animal models. This terpene may synergize with CBD to modulate peripheral inflammation, which could be relevant for exercise recovery and joint discomfort.
Pinene has been associated with alertness and bronchodilation in preclinical literature. In hemp flower, it may help counterbalance the sedative edge sometimes attributed to higher myrcene expressions, making Hemp #2 suitable for daytime calm.
For wellness users, common applications include stress management, post-workout recovery, and winding down in the evening. Because total THC is minimal when hemp is used as flower or vapor, the risk of intoxic
